Injectable PrEP use leads to zero new HIV infections among gay, trans and non-binary Brazilians
Once-yearly PrEP moves closer: experimental lenacapavir formulations show promise
Positive interactions with healthcare workers improve HIV care retention in Malawi and Zambia
Studies confirm non-inferiority of doravirine / islatravir to standard HIV treatment
Large fall in severe illnesses over two decades in Spain, while co-morbidities stay stable
Event-driven PrEP for women may work, modelling study predicts
PEPFAR study shows the deadly impact of stopping children’s HIV treatment
Lenacapavir plus broadly neutralising antibodies could be twice-yearly HIV treatment
Half the men in an HIV cure study stayed off treatment for nearly a year after a two-antibody shot
